Compound research & mechanism explainers

The investigational triple agonist (LY3437943): GLP-1, GIP and glucagon receptor targets, molecule properties, and what its published trials investigated.

How TB-500 relates to thymosin β4, the actin-sequestration biochemistry, and the predominantly preclinical models researchers have examined.

The copper tripeptide: copper(II) coordination chemistry, the mechanisms studied in fibroblast and gene-expression models, and evidence status.

A GHRH analog: the receptor mechanism and GH/IGF-1 axis, what the HIV-lipodystrophy trials measured, and its regulatory status.

A peptide encoded in mitochondrial DNA: AMPK/folate-cycle and mitochondrial-to-nuclear signalling, characterised mainly in cell and rodent models.

The coenzyme (not a peptide): its redox role, use as a substrate by sirtuins/PARPs/CD38, the NMN/NR precursor distinction, and appearance/stability.

A synthetic ACTH(4-10) analog: BDNF/TrkB and dopaminergic mechanisms, ischemia models, and the largely Russian-published evidence base.

A tuftsin-analog heptapeptide: GABAergic, BDNF, enkephalin and neuroimmune mechanisms examined, with honest treatment of the Russian literature.

A selective GH-secretagogue pentapeptide: the ghrelin-receptor (GHS-R1a) mechanism kept distinct from GHRH analogs, and the largely preclinical evidence base.

A GHRH analog: the GHRH-receptor mechanism, the DAC vs no-DAC (mod-GRF 1-29) chemistry distinction, and what published studies investigated.

A GHRH analog and the GH/IGF-1 axis — cross-referenced with the growth-hormone-secretagogue family.

A long-acting IGF-1 analog: receptor biology, IGFBP-binding and half-life properties studied in cell and animal models.

A synthetic fragment of growth hormone (hGH 177-191): the mechanisms researchers examined and its human-trial research history.

A melanocortin (MC1R/MC4R) receptor agonist: the melanocortin-system pharmacology studied in preclinical models.

A KISS1/GPR54 ligand upstream of GnRH: the HPG-axis signalling researchers have investigated.

The C-terminal α-MSH tripeptide (Lys-Pro-Val): the NF-κB / anti-inflammatory pathways examined in cell and rodent models.

A 28-amino-acid immunomodulatory peptide (Zadaxin): the immune-signalling mechanisms and clinical literature, reported neutrally.

A cardiolipin-binding Szeto-Schiller tetrapeptide (elamipretide): the mitochondrial mechanism studied in cell, animal and trial settings.

A phenothiazine dye (not a peptide): its redox chemistry and the electron-transport and enzyme mechanisms the literature has examined.

A synthetic tetrapeptide (Ala-Glu-Asp-Gly): the telomerase-expression and pineal mechanisms examined, largely in Russian/preclinical work.

Delta sleep-inducing peptide: the sleep-regulation and neuromodulatory roles investigated in a largely older, sparse literature.

A small-molecule NNMT inhibitor: the metabolic mechanisms examined in early, largely preclinical research.

An ERRα/β/γ agonist: the mitochondrial and metabolic pathways studied so far only in rodent models.

An angiotensin-IV-derived compound (HGF/c-Met modulator): the synaptogenesis mechanisms examined in preclinical models.

A porcine-brain peptide preparation: the neurotrophic mechanisms and the stroke/dementia clinical literature, reported neutrally.

What is in the Wolverine research blend — BPC-157 and TB-500 — with links to each component’s research and a plain note that the combination itself is unstudied.

What is in the GLOW research blend — GHK-Cu, BPC-157 and TB-500 — with links to each component’s research and a plain note that the combination itself is unstudied.

What is in the KLOW research blend — BPC-157, GHK-Cu, TB-500 and KPV — with links to each component’s research and a plain note that the combination itself is unstudied.

What is in the CJC-1295 + Ipamorelin blend, the different receptors each component targets, and a plain note that the combination itself is unstudied.